Loading...

Media is loading
 

Date of Award

Spring 2024

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Michelle Thal

Abstract

Even with a well-established treatment regimen, asthma is very prevalent and is continuously morphing. Step therapy is a generalized guideline for managing asthma but is not based on the pathophysiology of its subtypes. Currently, biological agents (also called monoclonal antibodies) are indicated for severe persistent asthma attacks. They are designed to target mechanisms of action and pathways to elicit an effect. This article explores the use of Omalizumab and Mepolizumab in comparison to one another. Both agents have indications for practicality of using biological agents given accessibility, cost, and the widespread presence of asthma.

Share

COinS
 

A Comparison of Omalizumab and Mepolizumab in Severe Asthma

Even with a well-established treatment regimen, asthma is very prevalent and is continuously morphing. Step therapy is a generalized guideline for managing asthma but is not based on the pathophysiology of its subtypes. Currently, biological agents (also called monoclonal antibodies) are indicated for severe persistent asthma attacks. They are designed to target mechanisms of action and pathways to elicit an effect. This article explores the use of Omalizumab and Mepolizumab in comparison to one another. Both agents have indications for practicality of using biological agents given accessibility, cost, and the widespread presence of asthma.